| Literature DB >> 31399369 |
Louise B Thingholm1, Malte C Rühlemann1, Manja Koch2, Brie Fuqua3, Guido Laucke1, Ruwen Boehm4, Corinna Bang1, Eric A Franzosa5, Matthias Hübenthal6, Ali Rahnavard5, Fabian Frost7, Jason Lloyd-Price5, Melanie Schirmer5, Aldons J Lusis3, Chris D Vulpe8, Markus M Lerch7, Georg Homuth9, Tim Kacprowski10, Carsten O Schmidt11, Ute Nöthlings12, Tom H Karlsen13, Wolfgang Lieb14, Matthias Laudes15, Andre Franke16, Curtis Huttenhower5.
Abstract
Obesity and type 2 diabetes (T2D) are metabolic disorders that are linked to microbiome alterations. However, their co-occurrence poses challenges in disentangling microbial features unique to each condition. We analyzed gut microbiomes of lean non-diabetic (n = 633), obese non-diabetic (n = 494), and obese individuals with T2D (n = 153) from German population and metabolic disease cohorts. Microbial taxonomic and functional profiles were analyzed along with medical histories, serum metabolomics, biometrics, and dietary data. Obesity was associated with alterations in microbiome composition, individual taxa, and functions with notable changes in Akkermansia, Faecalibacterium, Oscillibacter, and Alistipes, as well as in serum metabolites that correlated with gut microbial patterns. However, microbiome associations were modest for T2D, with nominal increases in Escherichia/Shigella. Medications, including antihypertensives and antidiabetics, along with dietary supplements including iron, were significantly associated with microbiome variation. These results differentiate microbial components of these interrelated metabolic diseases and identify dietary and medication exposures to consider in future studies.Entities:
Keywords: dietary supplements; iron; magnesium; medication; metabolic disease; microbiome; nutrition; obesity; type 2 diabetes
Mesh:
Substances:
Year: 2019 PMID: 31399369 PMCID: PMC7720933 DOI: 10.1016/j.chom.2019.07.004
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023